in 4 (18 %) out of 22 patients. Though this did not cause symptoms it nevertheless emphasizes t;he need to avoid giving gentamicin for minor sepsis. But in life--threatening Gramnegative sepsis in hospital practice we believe gentamicin therapy is the treatment of choice. There is still a tendency to give inadequate doses of gentamicin because of excessive anxiety about its toxicity. Inadequately-treated serious Gramnegative sepsis has a high mortality. The presenit series shows that vigorous but closely monitored gentamicin therapy gives excellent results without significant toxicity.
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We therefore recommend t-hat peak serum concentrations should be measured from the first day of treatment and the dose modified accordingly until values of at least 5 ,ug/ml or preferably 8-12 ,ug/ml are achieved. Dosage should be reduced only if concentrations exceed 15 ,ug/ml. Further assays of peak concentrations should be made when the dosage is altered. Trough concentrations as well as peaks should also be measured when there is a change in renal function and at least twice weekly during prolonged therapy. Closer monitoring is necessary during renal dialysis or the oliguric/anuric phase of acute renal failure. The more important function of monitoring is to ensure that adequate peak serum concentrations are reached as soon as possible, provided ,there is no severe renal dysfunction.
Salt-poor Human Albumin in Management of Nephrotic Syndrome

A. M. DAVISON, A. T. LAMBIE, A. H. VERTH, J. D. CASH
British Medical3Journal, 1974, 1, 481-484 Summary Thirteen patients with the nephrotic syndrome were treated with a high-protein diet, a 0-5 g sodium intake (equivalent to 1-3 g sodium chloride), and frusemide in increasing dosage. One became oedema-free with frusemide 240 mg daily, three became oedema-free with frusemide 500 mg daily, and two required a combination of high-dose frusemide and spironolactone. In three there was an appreciable increase in the blood urea, one patient developed hyponatraemia, and in two there was no weight loss. In these six patients infusions of human salt-poor albumin produced a prompt diuresis, loss of weight, and correction of the abnormal biochemical findings. In the seventh severely oedematous patient combined albumin and diuretic therapy led to a loss of 27 kg in 14 days.
Introduction
The management of severe nephrotic syndrome is based largely on diet and diuretics, though specific therapy may be used in some forms of glomerulonephritis-for example, corticosteroids in minimal lesion glomerulonephritis. Occa Janeway et al. (1944) undertook the first study of human albumin in this context and concluded ithat at least in the adult nephrotic patient it had no place; this conclusion was supported by Leutscher et al. (1949) . Recent reports, in which the importance of modern, powerful diuretics have been stressed, have included reference ito the occasional use of human albumin (Chamberlain et al., 1966; Garnet,t and Webber, 1967; Silverberg and Kjellstrand, 1968; Snashall, 1971) but contain little evidence that the introduction of albumin was really necessary or that i(t was specifically instrumental in inducing a diuresis. The proposed increase in the national capacity for plasma fractionation (Watt et al., 1972) (approximately 1-3 g sodium chloride); those with a blood urea of less than 100 mg/100 ml received 90 g protein daily.
Water was not restricted. All patients were fully mobile throughout treatment. Diuretic therapy was initiated with a single dose of 120 mg frusemide by mouth daily unless the patient was already receiving a higher dose at the time of referral. If after two days this had not induced a loss of weight of at least 1 kg the dose was increased to 250 mg daily by mouth and finally to 500 mg daily. Potassium supplements were given as required. Before the introduction of the 500-mg itablet the maximum dose used was 480 mg (12 x 40-mg tablets). If this failed to p-roduce a diuresis spironolactone 50 mg four times daily was added to ithe regimen provided there was no contraindication, such as hyperkaleaemia. After the introduction of spironolactone it was often necessary to reduce ithe potassium supplements. If a satisfactory weigh-t loss had not been achieved after five days of this combined therapy, or if complications developed (table II) , albumin infusions were added. Diuretic resistance was defined as a failure to lose 1 kg daily while on frusemide 500 mg, spironolactone 200 mg, and a diet containing 0 5 g sodium daily for a period of at least five days.
Results
Of the 12 patients referred to us for treatment of their nephrotic syndrome six responded to increased diuretic therapy (table II) ; one (case 1) lost a satisfactory amount of weight when frusemide was increased to 240 mg daily, three (cases 2, 3, and 4) became oedema-free with up to 500 mg frusemide daily, and two (cases 5 and 6) required the addition of spironolactone to achieve adequate weight loss. In all these patients more than 100 mEq of sodium was excreted in 24 hours. No adverse effects were noticed in this group with the exception of postural hypotension in case 3 ( fig. 1) 
Discussion
Prolonged proteinuria of more than 5 g a day results in hypoproteinaemia and development of the nephrotic syndrome. In patients with this syndrome complex and poorly understood physiological mechanisms come into play to maintain the plasma volume, and these coapensatory mechanisms may modify the response to diuretic drugs used in the treatment of oedema. The initial response to diuretic therapy in patients with the nephrotic syndrome is often good. Repeated administration of powerful diuretics, however, may further reduce the plasma volume and the glomerular filtration rate (Gamett and Webber, 1967; Jenkes et al., 1970) and in so doing accentte existing compensatory mechanisms. These changes could account for the develoPment of resistance to diuretic therapy in patients receiving frusemide for prolonged periods and for the rise in blood urea and fall in plasma sodium seen in some of those who continue to respond to the drug. The diuretic resistance seen in our patients appeared to be determined by the severity of the nephrotic syndrome, particularly -the severity of hypoproteinaeania, rather than the nature of the disease prxess.
Infusion of 15% salt-poor albumin increases the plasma oncotic pressure, which stimulates the reabsorption of water and electrolytes from the interstitial space; the plasma volume increases (Leutscher et al., 1949) , the glomerular filtration rate rises, and there is a reduction in the proximal tubular reabsorption of sodium and water (Knox, 1970; Brenner et al., 1969) . This results in an increa'sed delivery of sodium and water to ,the distal nephron which restores the capacity to respond -to diuretics such as frusemide. Hyponattraemia developing in the presence of persistent oodema, which has been reported by others (Fichman et al., 1971; Perez-Stable and Materson, 1971) , could result from impairment of urinary dilution and also from the action of antidiuretic hormone, which is released as a result of plasma volume contraction (Fichman et al., 1971) . In some of our patients the addition of albumin infusions was associated with a rapid restoration of the plasma sodium concentration ito normal despite a considerable natriuresis at a time when the sodium intake was maintained at a level of only 44 mEq a day ( fig. 4 ). Several accounts of the treatment of oedema have mentioned the use of albumin as an adjunct to therapy (Chamberlain et al., 1966; Garnett and Webber, 1967; Silverberg and Kjellstrand, 1968; Snashall, 1971) but its precise therapeutic role has not been defined. The early results of albumin therapy in the nephrotic syndrome were disappointing, and -this was thought to be due to loss of most of the infused protein in the urine (Janeway et al., 1944; Leutscher et al., 1949) . Moreover, albumin was expensive and difficult to obtain, and thus its use was virtually abandoned in favour of other agents, such as mannitol, dextran, and povidone, many of which proved {to have undesirable side effects (Rennie, 1956) . From this study it appears rthat albumin infusions musit be used in conjunction with effective diuretic (therapy, as very little of the sodium and water mobilized from the interstitial space is excreted unless a diuretic is given ( fig. 3 ). This probably accounts for the poor results obtained with albumin infusions before ithe introduction of powerful diuretic drugs.
This study suggests that infusions of salt-poor albumin are of value in restoring ,the capacity of patients wi,th the nephrotic syndrome to respond to moderately large doses of powerful diuretics. Irt is arguable that a diuresis might have been achieved in such patients by increasing the dose of the drug still further (Allison and Kennedy, 1971) , but prolonged administration of frusemide in large doses is associated in many cases with undesirable complications, such as postural hypotension, hyponatraemia, a fall in the glomerular fil-tration rate, and a rise in blood urea. Since these are likely to be due to contraction of the plasma volume a good case can be made for adding a plasma expander to the therapeutic regimen rather than increasing the dose of diuretics. In addition, as patients wi,tih the nephrotic syndrome have increased total body sodium (Farber and Soberman, 1956; Friis et al., 1970) it seems rational to use a salt-poor albumin concentrate rather than plasma, which contains approximately six times more sodium per gramme of albumin. Of no less importance is ithe absence of the risk of transmitting hepatitis when using albumin concentrates. This is particularly relevant to those nephrotic patients being treated by immunosuppressive therapy. Accordingly it appears rational to give infusions of salt-poor albumin -to patients with, the nephrotic syndrome who fail to achieve a satisfactory diuresis while receiving moderately large doses of frusemniide or ethacrynic acid and to those who develop -the complications of diuretic therapy mentioned above. In several of our patients it was possible to stop ithe albumin infusion¢s and stabilize (the patient on a lower dose of diuretcs once the oodema was reduced (figs. 3 and 4).
Though much of the infused albumin is excreted by the kidney up to 35 % may be retained by the body and will eventually be catabolized, producing essential components for further protein synthesis (Leutscher et al., 1949) . This may be of value to the nephrotic patient with a negative protein balance and is worthy of further studies. It would also be of interest to study the effect of albumin infusions early in the management of the nephrotic syndrome in an attempt to reduce the length of the inpatient care of these patients.
One of the purposes of this preliminary study was to ascertain whether there was a genuine need for human albumin in the management of patients with the nephrotic syndrome From the resu!ts obtained it seems that there are some patients in whom albumin infusions are essential to achieve complete resolution of oedema, and there are others in whom albumin infusion minimize ,the complications of diuretic therapy. It is likely that as it is introduced to therapeutic regimens more will be required than could be indicated from this group of patients. The complications of albumin infusions are few. There is a danger of precipitating cardiac failure by the rapid infusion of a plasma volume expander in the presence of diminished renal function, and care must be taken with the elderly or with any patient suspected of having poor cardiac function. We have given more than 150 infusions of albumin with no untoward reactions and consider this to be a safe form of therapy.
This study indicates -that infusions of 15% salt-poor human albumin are of value in treating patients with the nephrotic syndrome who are resistant -to diuretic therapy or who are developing undesirable complications such as uraemia or electrolyte imbalance. We suggest that in these circumstances 300 ml should be infused over a period of 45 minutes, provided there is no evidence of cardiac -failure, followed by an intravenous injection of 120 mg frusemide to establish a diuresis. The frequency of the infusions will depend on the size of the diuresis, but we suggest that initially they should be given on aLternate days.
